Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Dentistry
Volume 2016 (2016), Article ID 5070187, 6 pages
http://dx.doi.org/10.1155/2016/5070187
Case Report

Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case

1Oral-Head & Neck Oncology/Microvascular Surgery, Division of Oral & Maxillofacial Surgery and Division of Otolaryngology, John H. Stroger, Jr. Hospital of Cook County, 1900 W. Polk Street, Suite 612, Chicago, IL 60611, USA
2University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
3Advanced General Dentistry, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
4Department of Oral & Maxillofacial Surgery, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
5Department of Oral-Maxillofacial Surgery & Pathology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA

Received 15 February 2016; Revised 25 May 2016; Accepted 26 May 2016

Academic Editor: Noam Yarom

Copyright © 2016 Mohammed Qaisi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. L. Ruggiero, T. B. Dodson, J. Fantasia et al., “American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update,” Journal of Oral and Maxillofacial Surgery, vol. 72, no. 10, pp. 1938–1956, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Salari Sharif, M. Abdollahi, and B. Larijani, “Current, new and future treatments of osteoporosis,” Rheumatology International, vol. 31, no. 3, pp. 289–300, 2011. View at Publisher · View at Google Scholar
  3. M. R. Allen and D. B. Burr, “Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know,” Bone, vol. 49, no. 1, pp. 56–65, 2011. View at Publisher · View at Google Scholar
  4. I. S. Hamadeh, B. A. Ngwa, and Y. Gong, “Drug induced osteonecrosis of the jaw,” Cancer Treatment Reviews, vol. 41, no. 5, pp. 455–464, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. X.-L. Xu, W.-L. Gou, A.-Y. Wang et al., “Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?” Journal of Translational Medicine, vol. 11, article 303, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Diz, J. L. López-Cedrún, J. Arenaz, and C. Scully, “Denosumab-related osteonecrosis of the jaw,” Journal of the American Dental Association, vol. 143, no. 9, pp. 981–984, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Coleman, E. Woodward, J. Brown et al., “Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer,” Breast Cancer Research and Treatment, vol. 127, no. 2, pp. 429–438, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Vahtsevanos, A. Kyrgidis, E. Verrou et al., “Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5356–5362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. Amgen, Xgeva (denosumab) Highlights of Prescribing Information, Amgen, Thousand Oaks, Calif, USA, 2010.
  10. A. Xgeva Package Insert Highlights of Prescribing Information, 2010.
  11. L. S. Rosen, D. Gordon, M. Kaminski et al., “Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial,” Cancer, vol. 98, no. 8, pp. 1735–1744, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. T. L. Aghaloo, A. L. Felsenfeld, and S. Tetradis, “Osteonecrosis of the jaw in a patient on Denosumab,” Journal of Oral and Maxillofacial Surgery, vol. 68, no. 5, pp. 959–963, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. K. H. Taylor, L. S. Middlefell, and K. D. Mizen, “Osteonecrosis of the jaws induced by anti-RANK ligand therapy,” British Journal of Oral and Maxillofacial Surgery, vol. 48, no. 3, pp. 221–223, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. S. E. C. Pichardo, S. C. C. Kuypers, and J. P. R. van Merkesteyn, “Denosumab osteonecrosis of the mandible: a new entity? A case report,” Journal of Cranio-Maxillo-Facial Surgery, vol. 41, no. 4, pp. e65–e69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. M. S. Epstein, H. D. Ephros, and J. B. Epstein, “Review of current literature and implications of RANKL inhibitors for oral health care providers,” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol. 116, no. 6, pp. e437–e442, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. S. K. Tat, M. Padrines, S. Theoleyre et al., “OPG/membranous-RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation,” Bone, vol. 39, no. 4, pp. 706–715, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. D. L. Kendler, C. Roux, C. L. Benhamou et al., “Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy,” Journal of Bone and Mineral Research, vol. 25, no. 1, pp. 72–81, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. I. van der Waal and R. de Bree, “Second primary tumours in oral cancer,” Oral Oncology, vol. 46, no. 6, pp. 426–428, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Van den Wyngaert, K. Wouters, M. T. Huizing, and J. B. Vermorken, “RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?” Supportive Care in Cancer, vol. 19, no. 12, pp. 2035–2040, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. P. D. Miller, M. A. Bolognese, E. M. Lewiecki et al., “Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial,” Bone, vol. 43, no. 2, pp. 222–229, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Lipton, K. Fizazi, A. T. Stopeck et al., “Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials,” European Journal of Cancer, vol. 48, no. 16, pp. 3082–3092, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. J. A. Kanis, E. V. McCloskey, H. Johansson, C. Cooper, R. Rizzoli, and J.-Y. Reginster, “European guidance for the diagnosis and management of osteoporosis in postmenopausal women,” Osteoporosis International, vol. 24, no. 1, pp. 23–57, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Misso, M. Porru, A. Stoppacciaro et al., “Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid,” Cancer Biology and Therapy, vol. 13, no. 14, pp. 1491–1500, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Aghaloo, R. Hazboun, and S. Tetradis, “Pathophysiology of osteonecrosis of the jaws,” Oral and Maxillofacial Surgery Clinics of North America, vol. 27, no. 4, pp. 489–496, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. M. C. Walsh and Y. Choi, “Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond,” Frontiers in Immunology, vol. 5, article 511, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Iqbal, L. Sun, and M. Zaidi, “Denosumab for the treatment of osteoporosis,” Current Osteoporosis Reports, vol. 8, no. 4, pp. 163–167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Ramírez, R. M. A. López-Pintor, E. Casañas, L. D. Arriba, and G. Hernández, “New non-bisphosphonate drugs that produce osteonecrosis of the jaws,” Oral Health & Preventive Dentistry, vol. 13, no. 5, pp. 385–393, 2015. View at Publisher · View at Google Scholar · View at Scopus